Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
Colorectal Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory.
|
30481508 |
2019 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have used SW48 and LIM1215 human colon cancer cell lines, quadruple wild-type for KRAS, NRAS, BRAF and PI3KCA genes, and their HER2-amplified (LIM1215-HER2 and SW48-HER2) derived cells to perform in vitro and in vivo studies in order to identify novel therapeutic strategies in HER2 gene amplified human colorectal cancer.
|
31164152 |
2019 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutational status for KRAS, NRAS, and BRAF genes should be performed on all colorectal carcinoma (CRC) specimens in order to guide targeted therapy selection for metastatic disease.
|
31290252 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
|
31207216 |
2019 |
Colorectal Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In vitro experiments indicated that miR-144 decreased NRAS expression in different CRC cell lines (SW480, LoVo, and Caco2).
|
31693229 |
2019 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutations of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status have become an important part of the assessment of patients with colorectal cancer (CRC), while respective clinicopathologic features and prognostic significance in specific stages and related detection strategies remain unclear.
|
31162857 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although the presence of HER2 amplifications and oncogenic mutations in KRAS, NRAS, and BRAF are associated with EGFR-targeted therapy resistance, for a large population of CRC patients the underlying mechanism of RAS-MEK-ERK hyperactivation is not clear.
|
30858928 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the multivariate setting, left-sided CRC only turned out as a significant positive prognostic parameter regarding progression-free survival, irrespective of the type of chemotherapy or BRAF and NRAS mutations.
|
30711966 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating oncogenic mutations in KRAS and NRAS are common in CRC, driving tumor progression and influencing efficacy of both cytotoxic and targeted therapies.
|
31427573 |
2019 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The Japanese Society of Medical Oncology (JSMO) previously published 2 editions of the clinical guidelines: "Japanese guidelines for testing of KRAS gene mutation in colorectal cancer" in 2008 and "Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients" in 2014.
|
29873882 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Genomic biomarkers for the management of colorectal carcinoma are both well-established (ie, KRAS, NRAS) and emerging (BRAF, PIK3CA, and others) in respect to therapy selection and clinical trial eligibility.
|
29027537 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Large prospective clinical trials have shown only colorectal cancer (CRC) with wild-type KRAS and NRAS responds to anti-Epidermal Growth Factor Receptor treatment.
|
29921458 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes.
|
29959022 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In colorectal cancer, KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations are associated with resistance to antiepidermal growth factor receptor monoclonal antibodies, and BRAF mutation is a molecular marker of poor prognosis.
|
29052598 |
2018 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found "rare mutations" in RAS genes in nearly 14% of CRCs-i.e., in almost a quarter (24.0%) of KRAS exon 2 wild type CRCs, including 2.3% in KRAS exon 3, 8.2% in KRAS exon 4 and 3.4% in NRAS.
|
29666387 |
2018 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF).
|
29470838 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Indeed, activating mutations in the genes KRAS, NRAS and BRAF are the only predictive biomarkers for anti-EGFR antibody therapy routinely tested the clinic for advanced stages of CRC.
|
29788743 |
2018 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two-hundred and forty-two formalin-fixed paraffin-embedded (FFPE) human malignant colorectal cancer (CRC) tissue samples were identified in departmental archives and tested with both the Idylla NRAS-BRAF mutation test and the Agena Bioscience MassARRAY test.
|
28899979 |
2018 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
International guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-EGFR agents for metastatic colorectal cancer (CRC) patients.
|
29755687 |
2018 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
- To evaluate the significance of NRAS Q61R mutant-specific immunohistochemistry in a cohort of colorectal carcinomas.
|
28353383 |
2017 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS-mutation(+) CRC preferentially occurred in elder patients (P = 0.02) and at the distal colon (P = 0.006), showed significantly less lymph vessel invasion (P = 0.002), and correlated with LME (P = 8 × 10<sup>-5</sup> ).
|
28378457 |
2017 |
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
|
28560458 |
2017 |
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A subset of patients with metastatic CRC (n = 44) wild-type for KRAS, NRAS, and BRAF who received anti-epidermal growth factor receptor therapy with mutated SMAD4 (n = 13) had shorter progression-free survival duration than did patients wild-type for SMAD4 (n = 31) (median, 111 days versus 180 days; p = 0.003 [log-rank test]).
|
28267766 |
2017 |